Aarti Drugs share price
You have to be logged in to add this to Watchlist.- ₹475.35(-3.19%)July 8, 2025 15:29:35 PM IST
- NSE
- BSE
- Vol : 353.54K (NSE + BSE)Last 20 day avg : 358.80 K
Aarti Drugs is trading -3.19% lower at Rs 475.35 as compared to its last closing price. Aarti Drugs has been trading in the price range of 492.95 & 468.15. Aarti Drugs has given 6.62% in this year & 7.15% in the last 5 days. Aarti Drugs has TTM P/E ratio 18.50 as compared to the sector P/E of 23.19.There are 1 analysts who have initiated coverage on Aarti Drugs. There are - analysts who have given it a strong buy rating & - analysts have given it a buy rating. - analysts have given the stock a sell rating.The company posted a net profit of 62.85 Crores in its last quarter.Listed peers of Aarti Drugs include Suven Life Sciences (1.29%), Sequent Scientific (0.82%), Aarti Drugs (-3.19%).The Mutual Fund holding in Aarti Drugs was at 8.75% in 31 Mar 2025. The MF holding has increased from the last quarter. The FII holding in Aarti Drugs was at 2.25% in 31 Mar 2025. The FII holding has decreased from the last quarter.
- Overview
- Financials
- Forecast
- Technical Analysis
- Peers
- Shareholding
- About the company
- FAQ
Overview
Updated on Jul 08, 2025, 12:03 PM UTC
- Dividend YieldLower than industry0.21Annual dividends as a percentage of the stock price.
- P/BIn line with historical values3.25The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.
- P/EHigher than historical values26.51Price-to-earnings ratio based on trailing 12-month earnings
- BetaLow volatility0.61Beta measures a stock's volatility compared to the overall market. A beta > 1 indicates higher volatility than the market.
- Debt To EquityHigher than industry0.45The debt-to-equity ratio, indicating a company's financial leverage.
- PEG Ratio-The PEG ratio evaluates a stock's valuation by comparing its P/E ratio to its earnings growth rate. A lower PEG suggests better value relative to growth
|
| ||||
|
| ||||
- Income
- Balance Sheet
- Cash Flow
- Financial
- Valuation
Company is profitable- The company's revenue grew in March quarter by 9.16% from Rs 676.76 crore to Rs 619.99 crore, year-on-year
- The company has grown its March quarter profit by 32.85% from Rs 47.31 crore to Rs 62.85 crore, year-on-year
The debt to equity of the company is higher than the industry median- Company can comfortably pay off its interest obligations with its earnings
- R1
- 487.17
- R2
- 515.93
- R3
- 532.92
- S1
- 441.42
- S2
- 424.43
- S3
- 395.67
- Very Bearish
- Bearish
- Neutral
- Very Bullish
- Bullish
Names | Technical rating | Price | %Change | Market Cap | P/E | P/B | Dividend Yield | Debt to Equity |
|---|---|---|---|---|---|---|---|---|
| Suven Life Sciences | Bullish | 270.90 | 1.29 | 5,907.62 | - | 49.16 | - | - |
| Sequent Scientific | Neutral | 185.00 | 0.82 | 4,626.95 | 187.66 | 6.6 | - | 42.61 |
| Aarti Drugs | Bullish | 475.35 | -3.19 | 4,336.74 | 26.37 | 3.23 | 0.21 | 20.87 |
| Hikal | Bearish | 344.45 | 0.80 | 4,252.63 | 85.33 | 3.39 | 0.35 | 29.28 |
| Rpg Life Sciences | Bullish | 2,567.00 | -3.19 | 4,242.46 | 35.28 | 7.8 | 0.80 | - |
- Promoter(s) holds a high stake in the company at 55.48%
- Promoter(s) have decreased the stake in the company in last 12 months
- FIIs are invested in this company
- FIIs holding has decreased by 0.03 percentage points from previous quarter
- Mutual Funds holding has increased by 0.97 percentage points from previous quarter
- Board Meetings
- AGM
- Dividends
- Bonus
- Split
- Rights
| Meeting Date | Purpose |
|---|---|
| 2025-05-06 | Audited Results |
| 2025-01-29 | Quarterly Results & Interim Dividend |
| 2024-10-24 | Quarterly Results |
| 2024-08-26 | Buy Back of Shares |
| 2024-07-26 | Quarterly Results |
- IndustryBiotechnology & Drugs
- ISININE767A01016
- BSE Code524348
- NSE CodeAARTIDRUGS
Aarti Drugs is trading at 475.35 as on Tue Jul 08 2025 09:59:35. This is -3.19% lower as compared to its previous closing price of 491.00.
The market capitalization of Aarti Drugs is 4336.74 Cr as on Tue Jul 08 2025 09:59:35.
The 52 wk high for Aarti Drugs is 634.90 whereas the 52 wk low is 312.50
Aarti Drugs can be analyzed on the following key metrics -
- TTM P/E: 18.50
- Sector P/E: 23.19
- Dividend Yield: 0.20%
- D/E ratio: 0.45
Aarti Drugs reported a net profit of 168.16 Cr in 2025.
The Mutual Fund Shareholding was 8.75% at the end of 31 Mar 2025.